Myriad公司治疗血栓症的直接凝血酶抑制剂正在研制之中

 
一种新型口服的直接凝血酶抑制剂被设计用于更加迅速的可控制的发挥抗凝血效应，治疗窗口得以改善，患者的治疗反应可以预测，治疗效能也更好。

最常见的血栓症类型是发生在腿部的深静脉血栓症(DVT)。这种类型的血凝块能够破裂，通过腿和心脏，在肺部停留，导致动脉阻塞，这被称为肺部栓塞。当前使用的治疗这种疾病的药物，是肝素和华法令，但是这两种药物都有缺陷。肝素需要静脉用药和监测血压。肝素导致的血小板减少，或者血小板计数下降，是医院内最常见的严重药物反应。另一方面，华法令的治疗窗则非常小，能够导致非常严重的药物相互作用方面的问题。

这种新型抗凝血药物叫做MPC-0920，是由Myriad Genetics公司(Salt Lake City, UT, USA)研制开发的，该公司指出其临床前研究的资料已经接近完成。“MPC-0920是一种很有前景的化合物，在治疗领域十分重要。”  Myriad制药公司总裁Adrian Hobden博士说，“我们期望能够在这个财政年度，完成呈递给美国食品药品管理局的临床前研究资料。”

Antithrombin Drug in Development
 
A new orally available, direct thrombin inhibitor is designed to provide more rapid and predictable anticoagulant action, an improved therapeutic window, predictable patient response, and better efficacy.

The most common type of thrombosis is deep-vein thrombosis (DVT) in the leg. This type of clot can break apart, travel up the leg and through the heart, and lodge in the lungs, causing blockage of an artery, known as pulmonary embolism. The drugs currently used to treat this condition are heparin and warfarin, but both have drawbacks. Heparin requires intravenous administration and blood-level monitoring. Heparin-induced thrombocytopenia, or low platelet count, is the most common serious drug reaction in hospitals. Warfarin, on the other hand, has a very small therapeutic window and its use can result in serious drug interaction problems.

The new antithrombin drug, MPC-0920, was developed by Myriad Genetics, Inc. (Salt Lake City, UT, USA), which notes that it is rapidly nearing completion of the preclinical data. “MPC-0920 is an intriguing compound in a vitally important therapeutic area,” said Adrian Hobden, Ph.D., president of Myriad Pharmaceuticals, Inc. “We look forward to completing the preclinical data package for submission to the FDA [U.S. Food and Drug Administration] this fiscal year.”